(Q37797981)

23 August 2017

title

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications (English)

1 reference

23 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

2

Jorge Cortes

1 reference

23 August 2017

Javier Pinilla-Ibarz

1

1 reference

23 August 2017

Michael J Mauro

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

4 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

117

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

688-697

1 reference

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

EuroQol: the current state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Chronic myelogenous leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25648

21 January 2018

Identifiers

DOI

10.1002/CNCR.25648

1 reference

23 August 2017

1 reference